Antimicrobial Peptides / / edited by William M. Shafer.
With bacterial resistance and emerging infectious diseases becoming potential threats to humans, ribosomally synthesized antimicrobial peptides have become a promising focus area in antibiotic research. Antimicrobial peptides are classified as either non-ribosomally synthesized peptides or ribosomal...
Saved in:
TeilnehmendeR: | |
---|---|
Place / Publishing House: | [Place of publication not identified] : : MDPI - Multidisciplinary Digital Publishing Institute,, 2015. |
Year of Publication: | 2015 |
Language: | English |
Physical Description: | 1 online resource (xvi, 318 pages) :; illustrations |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993561975404498 |
---|---|
ctrlnum |
(CKB)4920000001372600 (NjHacI)994920000001372600 (EXLCZ)994920000001372600 |
collection |
bib_alma |
record_format |
marc |
spelling |
Antimicrobial Peptides / edited by William M. Shafer. [Place of publication not identified] : MDPI - Multidisciplinary Digital Publishing Institute, 2015. 1 online resource (xvi, 318 pages) : illustrations text txt rdacontent computer c rdamedia online resource cr rdacarrier Description based on publisher supplied metadata and other sources. With bacterial resistance and emerging infectious diseases becoming potential threats to humans, ribosomally synthesized antimicrobial peptides have become a promising focus area in antibiotic research. Antimicrobial peptides are classified as either non-ribosomally synthesized peptides or ribosomally synthesized peptides (RAMPs). Non-ribosomally synthesized peptides are found in bacteria and fungi. These antimicrobial peptides are assembled by peptide synthetases as opposed to ribosomal-supported synthesis. Gramicidin, bacitracin, polymyxin B, and vancomycin are examples of non-ribosomally synthesized antimicrobial peptides. These antibiotics are proven to be effective research tools, but compared to RAMPs they are disadvantageous for novel applications due to emerging bacterial resistance, for example vancomycin-resistant Staphylococcus aureus and enterococci. RAMPs are derived from a diverse range of species, from prokaryotes to humans. Antimicrobial peptides comprise a host's natural defense against the daily exposure to millions of potential pathogens. These peptides may also possess antiviral, antiparasitic, and antineoplastic activities. Over 500 RAMPs have been described in the literature. Their unique antibiotic spectrum is determined by amino acid sequence and structural conformation. RAMPs are gene-encoded peptides consisting of 12-50 amino acids with very little genetic overlap. A lack of sequence homology between RAMPs is indicative of evolutionary optimization of form and function in the species environment. RAMPs are typically cationic peptides with at least half of the amino acid residues being hydrophobic and a smaller number of neutral or negatively charged residues. Their amphipathic structure with opposing hydrophobic and lipohphilic faces aids in the perturbation of the bacterial cell wall. The mechanism of action of a RAMP involves peptide binding to the bacterial cell surface, conformational change to the peptide, aggregation of multiple peptide monomers, and pore formation through the bacterial cell wall. RAMPs bind to lipopolysaccharides in the negatively-charged, Gram-negative bacterial outer cell wall or to the acidic polysaccharides of the Gram-positive bacterial outer cell wall. After binding, permeabilization of the bilayer membrane occurs by transient pore creation. Permeabilization leads to a leakage of cell components and cell death. There are several models of permeabilization although the precise mechanism is unknown. Three permeabilization models are termed barrel-stave, thoroidal, and carpet. Figure 1. depicts bacterial cell wall perturbation by a RAMP. Cell Culture Contamination Troubleshooting -- Streptococci - Overview of Detection, Identification, Differentiation and Cultivation Techniques -- Introduction to Microbial Media -- Introduction to Microbial Media -- Inhibition of Cell Wall Biosynthesis by Antibiotics -- Lactobacilli -- Overview of Chromogenic Media -- Media for Staphylococcus Aureus Detection. Peptide antibiotics. 3-03842-073-5 Shafer, William M., editor. |
language |
English |
format |
eBook |
author2 |
Shafer, William M., |
author_facet |
Shafer, William M., |
author2_variant |
w m s wm wms |
author2_role |
TeilnehmendeR |
title |
Antimicrobial Peptides / |
spellingShingle |
Antimicrobial Peptides / Cell Culture Contamination Troubleshooting -- Streptococci - Overview of Detection, Identification, Differentiation and Cultivation Techniques -- Introduction to Microbial Media -- Introduction to Microbial Media -- Inhibition of Cell Wall Biosynthesis by Antibiotics -- Lactobacilli -- Overview of Chromogenic Media -- Media for Staphylococcus Aureus Detection. |
title_full |
Antimicrobial Peptides / edited by William M. Shafer. |
title_fullStr |
Antimicrobial Peptides / edited by William M. Shafer. |
title_full_unstemmed |
Antimicrobial Peptides / edited by William M. Shafer. |
title_auth |
Antimicrobial Peptides / |
title_new |
Antimicrobial Peptides / |
title_sort |
antimicrobial peptides / |
publisher |
MDPI - Multidisciplinary Digital Publishing Institute, |
publishDate |
2015 |
physical |
1 online resource (xvi, 318 pages) : illustrations |
contents |
Cell Culture Contamination Troubleshooting -- Streptococci - Overview of Detection, Identification, Differentiation and Cultivation Techniques -- Introduction to Microbial Media -- Introduction to Microbial Media -- Inhibition of Cell Wall Biosynthesis by Antibiotics -- Lactobacilli -- Overview of Chromogenic Media -- Media for Staphylococcus Aureus Detection. |
isbn |
3-03842-073-5 |
callnumber-first |
R - Medicine |
callnumber-subject |
RS - Pharmacy |
callnumber-label |
RS431 |
callnumber-sort |
RS 3431 P37 A585 42015 |
illustrated |
Illustrated |
dewey-hundreds |
600 - Technology |
dewey-tens |
610 - Medicine & health |
dewey-ones |
615 - Pharmacology & therapeutics |
dewey-full |
615.1 |
dewey-sort |
3615.1 |
dewey-raw |
615.1 |
dewey-search |
615.1 |
work_keys_str_mv |
AT shaferwilliamm antimicrobialpeptides |
status_str |
n |
ids_txt_mv |
(CKB)4920000001372600 (NjHacI)994920000001372600 (EXLCZ)994920000001372600 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Antimicrobial Peptides / |
author2_original_writing_str_mv |
noLinkedField |
_version_ |
1764993690100563968 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03969nam a2200289 i 4500</leader><controlfield tag="001">993561975404498</controlfield><controlfield tag="005">20230329112014.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr |||||||||||</controlfield><controlfield tag="008">230329s2015 xx a o 000 0 eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)4920000001372600</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(NjHacI)994920000001372600</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)994920000001372600</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">NjHacI</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="c">NjHacl</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RS431.P37</subfield><subfield code="b">.A585 2015</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">615.1</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Antimicrobial Peptides /</subfield><subfield code="c">edited by William M. Shafer.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">[Place of publication not identified] :</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute,</subfield><subfield code="c">2015.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (xvi, 318 pages) :</subfield><subfield code="b">illustrations</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on publisher supplied metadata and other sources.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">With bacterial resistance and emerging infectious diseases becoming potential threats to humans, ribosomally synthesized antimicrobial peptides have become a promising focus area in antibiotic research. Antimicrobial peptides are classified as either non-ribosomally synthesized peptides or ribosomally synthesized peptides (RAMPs). Non-ribosomally synthesized peptides are found in bacteria and fungi. These antimicrobial peptides are assembled by peptide synthetases as opposed to ribosomal-supported synthesis. Gramicidin, bacitracin, polymyxin B, and vancomycin are examples of non-ribosomally synthesized antimicrobial peptides. These antibiotics are proven to be effective research tools, but compared to RAMPs they are disadvantageous for novel applications due to emerging bacterial resistance, for example vancomycin-resistant Staphylococcus aureus and enterococci. RAMPs are derived from a diverse range of species, from prokaryotes to humans. Antimicrobial peptides comprise a host's natural defense against the daily exposure to millions of potential pathogens. These peptides may also possess antiviral, antiparasitic, and antineoplastic activities. Over 500 RAMPs have been described in the literature. Their unique antibiotic spectrum is determined by amino acid sequence and structural conformation. RAMPs are gene-encoded peptides consisting of 12-50 amino acids with very little genetic overlap. A lack of sequence homology between RAMPs is indicative of evolutionary optimization of form and function in the species environment. RAMPs are typically cationic peptides with at least half of the amino acid residues being hydrophobic and a smaller number of neutral or negatively charged residues. Their amphipathic structure with opposing hydrophobic and lipohphilic faces aids in the perturbation of the bacterial cell wall. The mechanism of action of a RAMP involves peptide binding to the bacterial cell surface, conformational change to the peptide, aggregation of multiple peptide monomers, and pore formation through the bacterial cell wall. RAMPs bind to lipopolysaccharides in the negatively-charged, Gram-negative bacterial outer cell wall or to the acidic polysaccharides of the Gram-positive bacterial outer cell wall. After binding, permeabilization of the bilayer membrane occurs by transient pore creation. Permeabilization leads to a leakage of cell components and cell death. There are several models of permeabilization although the precise mechanism is unknown. Three permeabilization models are termed barrel-stave, thoroidal, and carpet. Figure 1. depicts bacterial cell wall perturbation by a RAMP.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Cell Culture Contamination Troubleshooting -- Streptococci - Overview of Detection, Identification, Differentiation and Cultivation Techniques -- Introduction to Microbial Media -- Introduction to Microbial Media -- Inhibition of Cell Wall Biosynthesis by Antibiotics -- Lactobacilli -- Overview of Chromogenic Media -- Media for Staphylococcus Aureus Detection.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Peptide antibiotics.</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03842-073-5</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shafer, William M.,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-04-15 12:14:40 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-09-22 08:09:39 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338582490004498&Force_direct=true</subfield><subfield code="Z">5338582490004498</subfield><subfield code="8">5338582490004498</subfield></datafield></record></collection> |